Inflammatory Bowel Disease – Crohn’s Disease & Ulcerative Colitis

The Virginia Mason Digestive Disease Institute research program offers clinical trials in conjunction with the Inflammatory Bowel Disease Center of Excellence and Benaroya Research Institute.

Currently enrolling clinical research studies related to inflammatory bowel diseases:

• Ulcerative Colitis
   

• A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy
   

• A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis
   
• Crohn's
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy
   
• A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction and Maintenance Treatment for Patients with Moderately to Severely Active Crohn’s Disease
   
• A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease
   

If you would like to talk with a clinical research coordinator about liver disease clinical research trials, call the Digestive Disease Institute Research hotline at (206) 341-1021 or send an email to DDIResearchReferral@virginiamason.org.